Market Place
Sourcing Support
Scinai to Showcase Biologics CDMO and I&I Pipeline at BIO-Europe
31 Oct 2024 //
PR NEWSWIRE
Scinai To Host Expert Panel On Plaque Psoriasis Treatment
16 Sep 2024 //
PR NEWSWIRE
Scinai Regains Full Compliance with Nasdaq Listing Requirements
29 Aug 2024 //
PR NEWSWIRE
Scinai Closes Loan Restructuring Agreement With European Investment Bank
21 Aug 2024 //
PR NEWSWIRE
Scinai Reports Q2 2024 Results, Restructures Loan, On Track For Nasdaq
15 Aug 2024 //
PR NEWSWIRE
Scinai Immunotherapeutics Reports Promising Results In Psoriatic Skin Model
15 Jul 2024 //
PR NEWSWIRE
Scinai Immunotherapeutics Gets EU Investment Bank LOI For Loan-To-Equity Terms
08 Jul 2024 //
PR NEWSWIRE
Scinai Granted Nasdaq Extension To Regain Listing Compliance
03 Jul 2024 //
PR NEWSWIRE
Scinai Publishes Q1 2024 Financial Results and Provides Business Update
02 Jul 2024 //
PR NEWSWIRE
Scinai Gets EIB Terms For Loan To Equity Conversion Letter Of Intent
13 Jun 2024 //
PR NEWSWIRE
Scinai Regains Nasdaq Bid Price Compliance, Working To Convert EIB Loan
07 Jun 2024 //
PR NEWSWIRE
Scinai Nasdaq Determination Hearing: Equity Deficiency Compliance Plan Required
24 May 2024 //
PR NEWSWIRE
Scinai FY 2023 financial Result & Business Update
15 May 2024 //
PRESS RELEASE
Scinai Immunotherapeutics Nasdaq Delisting Notice, Appeals
06 May 2024 //
PR NEWSWIRE
Scinai To Present Novel Psoriasis Therapy At Dermatology Summit With Prof Schön
10 Apr 2024 //
PRESS RELEASE
Ayana Pharma Signs Master Service Agreement with Scinai Immunotherapeutics
08 Apr 2024 //
PRNEWSWIRE
Scinai leadership to attend BIO-Europe Spring 2024
12 Mar 2024 //
PR NEWSWIRE
Ratio Announces Expansion of Manufacturing Agreement with PharmaLogic
12 Mar 2024 //
PR NEWSWIRE
Scinai to showcase its cGMP biologics CDMO and innovative NanoAb pipeline
29 Feb 2024 //
PR NEWSWIRE
Scinai Welcomes Liat Halpert as Head of Business Development and Sales
13 Feb 2024 //
PR NEWSWIRE
Scinai Congratulates Research Collaborator Dirk Görlich on Louis-Jeantet Prize
25 Jan 2024 //
PR NEWSWIRE
Scinai Immunotherapeutics CEO Issues Letter to Shareholders
04 Jan 2024 //
PR NEWSWIRE
Scinai Announces Closing of Exercise of Outstanding Warrants for $1.69 Million
04 Jan 2024 //
PR NEWSWIRE
Scinai Announces Exercise of Outstanding Warrants for $1.69M in Gross Proceeds
29 Dec 2023 //
PR NEWSWIRE
Scinai (NASDAQ: SCNI) to Host Analyst and Investor Webinar on January 9
27 Dec 2023 //
PR NEWSWIRE
Scinai Announces Promising Results in a Psoriatic Human Skin Model
12 Dec 2023 //
PR NEWSWIRE
Study published in Research supports promise of Scinai`s coronavirus NanoAb
11 Dec 2023 //
PR NEWSWIRE
Scinai Immunotherapeutics Announces Award of Non-Dilutive Grant
06 Nov 2023 //
GLOBENEWSWIRE
Scinai Immunotherapeutics Provides Update Regarding Nasdaq Compliance
03 Nov 2023 //
GLOBENEWSWIRE
Scinai Reports Third Quarter 2023 Financial Results and Provides Business Update
31 Oct 2023 //
GLOBENEWSWIRE
EIB considering extending maturity of its financial facility contract
31 Oct 2023 //
GLOBENEWSWIRE
Scinai Immunotherapeutics to Attend BIO-Europe Munich 2023
30 Oct 2023 //
GLOBENEWSWIRE
Scinai to Showcase its end-to-end cGMP Biologics CDMO Services at CPHI
04 Oct 2023 //
GLOBENEWSWIRE
Scinai Announces Closing of $1.33 Million Registered Direct Offering
19 Sep 2023 //
GLOBENEWSWIRE
Scinai Immunotherapeutics Announces $1.33 Million Registered Direct Offering
15 Sep 2023 //
GLOBENEWSWIRE
BiondVax Rebrands as Scinai to Reflect Focus on Development of I&I Therapeutics
06 Sep 2023 //
GLOBENEWSWIRE
BiondVax Reports Second Quarter Financial Results and Provides Business Update
11 Aug 2023 //
GLOBENEWSWIRE
Nasdaq Grants BiondVax Extension to Regain Compliance with Listing Rules
01 Aug 2023 //
GLOBENEWSWIRE
BiondVax signs agreement for development of a novel anti-IL-17 antibody
05 Jun 2023 //
GLOBENEWSWIRE
BiondVax Files FY 2022 Financial Statements and Annual Report
17 Apr 2023 //
GLOBENEWSWIRE
BiondVax to Present at BIO-Europe Spring
16 Mar 2023 //
GLOBENEWSWIRE
BiondVax Presenting at BIO CEO & Investor Conference
02 Feb 2023 //
GLOBENEWSWIRE
BiondVax`s Inhaled Anti-SARS-CoV-2 NanoAb Virtually Prevented Illness
23 Jan 2023 //
GLOBENEWSWIRE
BiondVax`s Innovative Inhaled COVID-19 Therapy Virtually SARS-COV-2 Virus
06 Jan 2023 //
GLOBENEWSWIRE
BiondVax Announces Pricing of $8 Million Underwritten Public Offering
16 Dec 2022 //
GLOBENEWSWIRE
BiondVax Regains Nasdaq Compliance
12 Dec 2022 //
GLOBENEWSWIRE
Professor Dr. Matthias Dobbelstein joins BiondVax’s SAD
06 Dec 2022 //
GLOBENEWSWIRE
IBN (InvestorBrandNetwork) Coverage Initiated for BiondVax Pharmaceuticals Ltd.
06 Dec 2022 //
GLOBENEWSWIRE
BiondVax announces 3Q 2022 Financial Results and Provides Business Update
30 Nov 2022 //
GLOBENEWSWIRE
BiondVax reports successful results in preclinical in vivo study
29 Nov 2022 //
GLOBENEWSWIRE
BiondVax CEO to Present at the January 2023 Biotech Showcase in San Francisco
21 Nov 2022 //
PRNEWSWIRE
BiondVax to present at Advances in Fermentation Technology (RAFT) 14 Conference
03 Nov 2022 //
PRNEWSWIRE
BiondVax provides plan to address Nasdaq compliance
02 Nov 2022 //
PRNEWSWIRE
BiondVax to present at LD Micro Investor Conference in Los Angeles
11 Oct 2022 //
PRNEWSWIRE
BiondVax announces financial plans to support its NanoAb pipeline development
30 Sep 2022 //
PRNEWSWIRE
BiondVax`s Strategic Research Collaboration with Max Planck and UMG
20 Sep 2022 //
PRNEWSWIRE
BiondVax to Present at H.C. Wainwright 24th Annual Global Investment Conference
08 Sep 2022 //
PRNEWSWIRE
BiondVax announces Second Quarter 2022 Financial Results
25 Aug 2022 //
PRNEWSWIRE
BiondVax and European Investment Bank sign definitive amendment extending
10 Aug 2022 //
PRNEWSWIRE
BiondVax gets Scientific Advice from PEI for COVID-19 NanoAb development plans
07 Jun 2022 //
PRNEWSWIRE
